Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dual chimeric antigen receptor cytokine-induced killer cells IL-3z WT (Mustang Bio)
- Development stage
- Unknown
- Lead developer
- Mustang Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**Dual chimeric antigen receptor cytokine-induced killer cells IL-3z WT** appears to denote an experimental engineered cytokine-induced killer cell product carrying a wild-type interleukin-3-based, CD3-zeta-signaling chimeric antigen receptor. The interleukin-3 recognition element is intended to direct cytotoxic CIK cells toward cells expressing the interleukin-3 receptor alpha subunit, also known as CD123, a myeloid malignancy-associated antigen. The term \"dual\" indicates that the cellular construct incorporates two CAR elements, but the identity and signaling architecture of any additional CAR are not established from the supplied name alone.
- Other names
- IL-3z WTIL3z WTIL 3z WT
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)IL13RA2 (Interleukin-13 receptor subunit alpha 2)IL13RA1 (Interleukin-13 receptor subunit alpha-1)
Beyond the preview
Go deeper on dual chimeric antigen receptor cytokine-induced killer cells IL-3z WT (Mustang Bio).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dual chimeric antigen receptor cytokine-induced killer cells IL-3z WT (Mustang Bio).